Why Voyager Therapeutics Stock Is Sinking Today
Shares of the clinical-stage gene therapy company Voyager Therapeutics (NASDAQ: VYGR) dropped by as much as 11% in pre-market trading Tuesday morning. The biotech's shares are responding negatively to a regulatory delay for its Huntington's disease candidate, VY-HTT01. After market close yesterday, Voyager announced that the Food and Drug Administration placed a clinical hold on the experimental gene therapy pending the resolution of certain chemistry, manufacturing, and controls (CMC) matters.
